Xiaoyu Liu

Dr. Xiaoyu Liu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XZXu Zhang
Xu Zhang
YZYanxian Zhang
Yanxian Zhang
XLXiaoyu Liu
Xiaoyu Liu
YJYuxiang Ji
Yuxiang Ji
YLYongmei Lyu
Yongmei Lyu
XLXiaoyu Liu
Xiaoyu Liu
Peripheral nerve injury (PNI) represents a common challenge in clinical practice. In contrast to the central nervous system (CNS), the peripheral nervous system (PNS) in mature mammals possesses a limited regenerative capacity. Upon the occurrence of PNI, peripheral nerve regeneration (PNR) is initiated, facilitated by the activation of the immune microenvironment and the intrinsic growth potential of neurons. This regenerative process encompasses several key stages, including distal axon degeneration, myelin breakdown, clearance of myelin debris, inflammatory responses from non-neuronal cells, and subsequent axonal regeneration. The immune response, recognized for its role in clearing myelin debris and modulating the local inflammatory milieu, is crucial for initiating axonal regeneration at the proximal stump of nerves. Nevertheless, the precise mechanisms by which the immune response influences PNI and the strategies to harness this process to augment regeneration remain elusive. This article provides a comprehensive overview of the diverse roles and mechanisms of the immune system in PNR and presents insights into potential therapeutic strategies. Furthermore, the article examines immune-associated signaling pathways and their impact on PNR, underscoring the significance of immune modulation in enhancing patient outcomes with PNI. Ultimately, it encapsulates and forecasts the theoretical and practical directions of this field.

1 November 2024 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
LYLili Yao
Lili Yao
JXJie Xu
Jie Xu
XZXu Zhang
Xu Zhang
ZTZhuqi Tang
Zhuqi Tang
XLXiaoyu Liu
Xiaoyu Liu
XDXuChu Duan
XuChu Duan
Introduction: Endoplasmic reticulum stress (ERS) is a prominent etiological factor in the pathogenesis of diabetes. Nevertheless, the mechanisms through which ERS contributes to the development of diabetes remain elusive.Methods: Transcriptional expression profiles from the Gene Expression Omnibus (GEO) datasets were analyzed and compared to obtain the differentially expressed genes (DEGs) in T2DM. Following the intersection with ERS associated genes, the ERS related T2DM DEGs were identified. Receiver operating characteristic (ROC) and Least Absolute Shrinkage and Selection Operator (LASSO) analysis were performed to screen out the ERS related biomarker genes and validate their diagnostic values. Gene expression level was detected by qPCR and Elisa assays in diabetic mice and patient serum samples.Results: By analyzing the transcriptional expression profiles of the GEO datasets, 49 T2DM-related DEGs were screened out in diabetic islets. RTN1, CLGN, PCSK1, IAPP, ILF2, IMPA1, CCDC47, and PTGES3 were identified as ERS-related DEGs in T2DM, which were revealed to be involved in protein folding, membrane composition, and metabolism regulation. ROC and LASSO analysis further screened out CLGN, ILF2, and IMPA1 as biomarker genes with high value and reliability for diagnostic purposes. These three genes were then demonstrated to be targeted by the transcription factors and miRNAs, including CEBPA, CEBPB, miR-197-5p, miR-6133, and others. Among these miRNAs, the expression of miR-197-5p, miR-320c, miR-1296-3P and miR-6133 was down-regulated, while that of miR-4462, miR-4476-5P and miR-7851-3P was up-regulated in diabetic samples. Small molecular drugs, including D002994, D001564, and others, were predicted to target these genes potentially. qPCR and Elisa analysis both validated the same expression alteration trend of the ERS-related biomarker genes in diabetic mice and T2DM patients.Discussion: These findings will offer innovative perspectives for clinical diagnosis and treatment strategies for T2DM.

23 August 2025 in Molecular and Cellular Probes
Verified
Journal Article
Open access
YNYanyan Niu
Yanyan Niu
XZXu Zhang
Xu Zhang
XLXiaoyu Liu
Xiaoyu Liu
XCXiaodong Chen
Xiaodong Chen
XLXiaoyu Liu
Xiaoyu Liu
XYXiaodong Yao
Xiaodong Yao
Keloids are benign dermal proliferations resulting from excessive fibroblast activity that extends beyond the original site of injury. This study aims to investigate key biomarker genes associated with cell apoptosis and proliferation in the pathogenesis of keloids. Bioinformatic analysis of Gene Expression Omnibus datasets identified 122 differentially expressed genes (DEGs) in samples from keloid patients. Following the intersection with apoptosis-related genes (ARGs), three DEGs-ANLN, CLU, and SFRP2-were identified as keloid-associated ARGs. Among these, the expression of CLU was consistently reduced across both training and validation datasets. Experimental validation confirmed the expression alteration of CLU in keloid patient samples and further revealed that the expression of secreted CLU (sCLU) was significantly decreased in keloid fibroblasts. At the same time, BAX was down-regulated while BCL2 was up-regulated. Overexpression of sCLU in keloid derived primary fibroblasts significantly promoted apoptosis and reduced the viability of the cells, accompanied with up-regulated BAX and down-regulated BCL2, and fibrotic factor genes, such as collagen I, collagen III, α-SMA and CTGF. In contrast, serum levels of CLU did not differ significantly between keloid patients and non-related controls, suggesting limited utility of circulating CLU as a diagnostic biomarker. Taken together, these findings reveal a crucial role of sCLU in keloid pathogenesis, thereby presenting a potential tissue-level biomarker for keloid diagnosis and a promising therapeutic target.